|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3713 USD | +0.76% |
|
+3.43% | -72.29% |
| 06-08 | Soligenix Applies for Vaccine Development Funding for Bundibugyo Ebola Vaccine | CI |
| 05-28 | Soligenix - increases maximum offering under sales agreement by $2.96 million | RE |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 5.5M | - | - | - | - | - |
| 57.28B | |||||
| 54.99B | |||||
| 23.18B | - | ||||
| 22.59B | - | ||||
| 20.46B |
- Stock Market
- Stocks
- SNGX Stock
- Charts Soligenix, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
